Review

Receptor-Mediated Drug Delivery Systems Targeting to Glioma

Shanshan Wang, Ying Meng, Chengyi Li, Min Qian and Rongqin Huang *

Received: 25 September 2015; Accepted: 24 November 2015; Published: 28 December 2015
Academic Editors: Subramanian Tamil Selvan, Wolfgang J. Parak and Pablo del Pino

Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China; 14211030067@fudan.edu.cn (S.W.); today20090713@126.com (Y.M.); 11307120164@fudan.edu.cn (C.L.); 12307120146@fudan.edu.cn (M.Q.)
* Correspondence: rqhuang@fudan.edu.cn; Tel./Fax: +86-21-5198-0078

Abstract: Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.

Keywords: glioma; blood-brain barrier (BBB); receptor-mediated; single ligand-modified targeting systems; dual ligand-modified targeting systems

1. Introduction

Glioma, which arises from glial cells, is by far the most frequent and lethal brain tumor, accounting for approximately 80% of malignant tumors in the central nervous systems (CNS) [1,2]. According to the growing speed and the infiltration extent to nearby brain tissues, glioma can be categorized to low-grade (World Health Organization (WHO) grades I and II), as well as high-grade (WHO grades III and IV) [3]. Even in combination of currently most effective therapies such as surgery, radiotherapy, and chemotherapy, median survival for high-grade glioma still remains gloomy (14.6 months) [4,5]. This might be attributed to specific properties of glioma, such as the highly infiltrative nature and lack of clear margins. In addition, the physical and chemical constraints of the blood-brain barrier (BBB) are also primary obstacles to the multimodality therapies for glioma [6–9].

The BBB is made up of brain capillary endothelial cells (BCECs) which are joined together by tight junctions. It plays an important role as a selective barrier and a critical regulator of brain homeostasis, separating the brain from circulating toxins and potentially harmful chemicals, and allowing access of a small subset of molecules with the appropriate size (400–600 Da), charge, and lipid solubility [8,10–12]. Furthermore, drug delivery to the brain is also restricted by a range of active efflux transporters present on the BBB and other contributing structures [8]. Hence, more than 98% small molecular drugs and almost all large molecules are barred from the brain tissues [13]. It has been reported that the BBB dysfunction is related to the increasing histological grade of glioma, which implies that the BBB is grossly intact at the early stage, and gradually disrupted with the progress of glioma [14]. Based on this occasion, the glioma-targeted drug delivery systems are mainly divided into two categories. When the BBB is intact, the systems which must deliver drugs across the BBB for tumor-targeting
are defined as cascade-targeting systems. Other drug delivery systems utilized in high-grade glioma are designated as glioma-targeting systems, which mainly accumulated in the glioma by enhanced permeation retention (EPR) effect.

In recent years, plenty of strategies have been developed for overcoming the BBB and/or targeting to glioma such as receptor-, transporter-, or adsorption-mediated drug delivery according to different transport mechanisms [15,16]. As one of the major approaches, receptor-mediated drug delivery has been extensively studied over the past decade. This kind of drug delivery systems are comprised of nanocarriers (such as liposomes, nanoparticles (NPs), polymeric micelles, dendrimers and polymersomes), and various ligands targeting to different receptors including transferrin receptor (TfR), lactoferrin receptor (LfR), low-density lipoprotein receptor (LDLR), and folate receptor (FR) [17–20]. In this review, recent progress on receptor-mediated drug delivery systems targeting glioma is summarized according to the amount and type of the targeting moieties.

2. Single Ligand-Modified Targeting Systems

The single ligand-modified drug delivery systems are conjugated with just one ligand that could target to both BBB and glioma, or glioma alone, which could realize cascade-targeting or glioma-targeting functions, respectively. The detailed illustration of the single ligand-modified targeting systems are shown in Figure 1 and their information are summarized in Table 1.

![Figure 1. Schematic representation of single ligand-modified targeting systems.](image)

### Table 1. Representative single ligand-modified targeting systems.

| Targeting Site | BCECs | Glioma | Targeting Moiety | Nanocarrier | References |
|---------------|-------|--------|-----------------|-------------|------------|
| TfR           | √     | √      | Tf              | PEGylated nanoscaled GO [21] |
|               |       |        | OX26            | Magnetic silica PLGA NPs [17] |
|               |       |        | T7              | Immunomicelles [22] |
|               |       |        | T7              | Dendrigraft poly-L-lysine [23] |
|               |       |        | T7              | Dendrigraft poly-L-lysine [24] |
|               |       |        | T7              | TFR-lytic hybrid peptide [25,26] |
| LfR           | √     | √      | Lf              | Superparamagnetic iron oxide NPs [27] |
Table 1. Cont.

| Targeting Site | BCECs | Glioma | Targeting Moiety | Nanocarrier | References |
|----------------|-------|--------|------------------|-------------|------------|
| LDLR           | √     | √      | nLDL Peptide-22  | nLDL PEG-PLA NPs | [28]        |
| LRP            | √     | √      | Angiopep-2       | Gold NPs PEG-PCL NPs | [30] [31]   |
| FR             | √     | √      | Folate           | MnO NPs PEGylated PEI | [33] [34]   |
| Insulin Receptor | √     | √      | 83-14 murine monoclonal antibody | PEGylated immunoliposomes | [35] |
| Interleukin-13 Receptor | ×     | √      | IL-13(IP)        | Mesoporous silica NPs Mesoporous silica-coated graphene nanosheet | [36] [37] |
| Integrin       | ×     | √      | RGD               | Nanochain | [38] |

2.1. Cascade-Targeting Systems

Some receptors have been reported to be highly expressed on both BBB and glioma, which provide the cascade-targeting sites for receptor-mediated drug delivery systems. The single targeting ligand that could mediate both transportation of drugs across the BBB and their internalization into glioma cells is referred figuratively as a “multistage rocket”, which represents the simplest approach for secondary targeted delivery.

2.1.1. TfR-Mediated Targeting Systems

As an essential element of the human body, cellular iron plays a crucial role in cell proliferation [39,40]. The best characterized mechanism for iron uptake is mediated by the cell surface TfR, which is classified as TfR1 and TfR2 [41–44]. Both TfR1 and TfR2 are overexpressed in some proliferating cells such as BCECs and many malignant tumor cells [21,45]. In addition, TfR is also highly expressed in some normal tissues such as liver, which limits other specific targeting efficiency in vivo to some extent [43]. Lots of studies have reported that TfR could be used for mediating drug delivery systems to the glioma. These systems are designed to utilize various targeting moieties such as transferrin (Tf), antibodies or specific peptides to lead carriers directly to the diseased sites.

Since TfR was found as a highlighted target for mediating drugs across the BBB, many targeting moieties aiming at TfR have been discovered. As an innate ligand, Tf is a naturally-existing protein possessing high affinity for TfR [45]. Liu and colleagues constructed Tf-conjugated doxorubicin (DOX)-encapsulated PEGylated nanoscaled graphene oxide (GO) (Tf-PEG-GO-DOX) as a BBB-targeting anti-glioma drug delivery system [21]. Quantitative determination revealed that a faster transport rate and a 4.63 intensification of cell inhibition to C6 glioma cell were achieved with the conjugation of Tf. Consistent with these results, Tf-PEG-GO-DOX also exhibited stronger inhibitory effect on tumor growth. In addition, Cui and coworkers studied the Tf-conjugated magnetic silica poly(D,1-lactic-co-glycolic acid) (PLGA) NPs loading DOX and paclitaxel (PTX) (DOX-PTX-NPs-Tf) to bypass the BBB and subsequently target to the glioma [17]. It is showed that U87 glioma cells treated by the Tf-conjugated NPs have higher intracellular accumulation of drugs than unconjugated counterparts. Additionally, the in vivo anti-glioma studies demonstrated that DOX-PTX-NPs-Tf treatments resulted in a substantial reduction in tumor size compared to Tf-unconjugated NPs. More recently, the use of Tf in preparation of cascade-targeting anti-glioma drug delivery systems has risen sharply, which is related to the high affinity for TfR and the effective treatments in the past studies [21,44,46]. Such
conjugates with Tf have demonstrated enhanced cellular uptake via Tf-mediated mechanisms and increased selective cytotoxicity in glioma cells and tumor xenograft animal models. However, it has been reported that high concentration of endogenous Tf (2250 nM) may produce competitive inhibition to the Tf-modified drug delivery systems [20]. Therefore, some alternatives with similar affinity for TfR were developed. Many studies have demonstrated the capacity of anti-TfR antibodies to inhibit cell growth, especially for some malignant cells [47]. For example, OX26, a mouse monoclonal antibody against rat TfR1, has been developed as a targeting moiety for delivering drugs into the brain. The first use of OX26 for the delivery of therapeutic agents across the BBB was reported in the early nineties [48]. Recently, Yue and coworkers have prepared OX26 covalently linked immunomicelles and demonstrated a two-fold increase in intracellular drug concentration with the conjugation of OX26, indicating that the OX26 modification can increase the brain uptake of micelles through TfR-mediated endocytosis [22]. Some other anti-TfR antibodies including Ri7, 8D3, and 7579 also have great potential for cascade-targeting delivery. Although these antibodies have not been verified in this field, many related achievements opened the door for Ri7, 8D3, or 7579-mediated drug delivery systems. For example, the brain distribution of Ri7 and 8D3 were characterized by Paris-Robidas et al. [49]. They proved that fluorolabeled anti-TfR antibodies could readily accumulated into BCECs and the antibodies were able to attach to the TfR via measuring fluorescence in brain homogenates [49]. Despite the potentials of TfR targeting antibodies for drug delivery, the fact that preparation of these antibodies is difficult within rigorous laboratory conditions makes it hard to control their quality, and limits their development in real applications.

Recently, some peptides have been greatly impressed by considerable researchers due to their facile synthesis methods and high affinity for TfR. A seven peptide (HAIYPRH, T7) has been reported to specifically bind to TfR [50–52]. Its high affinity for TfR is comparable to that of Tf, with the Kd of approximately 10 nM [51]. Furthermore, the T7 binding site on TfR was reported to be different from that of Tf, which might avoid interference with endogenous Tf. Interestingly, the cellular uptake of T7-conjugated drug delivery systems was found to be accelerated when endogenous Tf bound with TfR [51]. Based on this research, Jiang’s group prepared a T7-modified co-delivery system loading DOX and anti-glioma gene medicine pORF-hTRAIL (DGDPT/pORF-hTRAIL) [23]. Results showed that the T7-modified co-delivery system enhanced the cellular uptake of DOX and pORF-hTRAIL, increased their brain accumulation, and prolonged the survival time of tumor-bearing mice, compared to the system without T7 modification. Further studies demonstrated a better RNA interference effect of T7-functionalized siRNA-encapsulated NPs compared to the unmodified counterparts [24]. Consensus was reached by others, which suggesting that the T7-modified nano-enabled drug delivery systems could cross the BBB, reach the glioma and be internalized by glioma cells [53,54]. In addition to T7, another targeting peptide used to bind with TfR is TfR-lytic hybrid peptide, a combination of the TfR-binding peptide and a lytic peptide. An intriguing study designed by Kawamoto et al. has drawn researchers’ attention recently [25,26]. The results showed that the peptide itself was a drug delivery system which could cross the BBB and target to the glioma via the TfR-binding peptide, and further lead to cancer cell death via lysis by the lytic peptide. Cytotoxic and binding activity of the TfR-lytic hybrid peptide were verified in murine glioma GL261 cells and human glioma U251 cells, and a significant inhibited effect of tumor growth was observed in in vivo anti-tumor studies. As mentioned above, both the T7 and the hybrid peptide can be exploited as appropriate candidates for clinical application owing to their advantage of small steric hindrance, stability and good mediators for crossing the BBB.

2.1.2. LfR-Mediated Targeting Systems

As a member of the Tf family, lactoferrin (Lf) is a single-chain cationic iron-binding glycoprotein [55]. The high concentration of endogenous Lf in human milk and its capacity to bind to the iron in breast milk suggested that Lf has a physiological function in the newborn infant [56,57]. Multiple biological activities of Lf are mediated by LfR [58]. According to some investigations on
binding kinetics of Lf to target cells, different tissues or cell types seem to express their own LfR, and their characteristics vary among different cell types. Several proofs have demonstrated the presence of specific LfR in the brain [59,60]. Moreover, LfR has been proved to not only exist on the BBB in different species but also on the cell surface of glioma, which makes it a potential cascade-targeting ligand [61,62]. Compared to Tf, Lf possesses two main advantages as a brain-targeting ligand. First, the plasma concentration of Lf is much lower (approximately 5 nM), avoiding the interference of endogenous Lf [63]. Second, the transport of Lf across the BBB is unilateral, decreasing the reverse transport of Lf-modified drug delivery systems from the brain to the blood circulation [64]. A number of studies have demonstrated LfR-mediated enhancement in therapeutic effects against glioma. Su and colleagues have successfully developed Lf-modified NPs as a targeting carrier for facilitating the uptake of DOX in brain tissue and treating glioma [18].

Apart from their therapeutic benefits, these receptor-mediated systems can also play a crucial role in diagnosis of glioma. The group of Yang explored Lf-conjugated magnetic nanogels (Lf-MPNA) as a MRI contrast agent for glioma detection in vivo [27]. The MR images of rats’ brains after injection with Lf-MPNA nanogels displayed more significant contrast enhancement in the tumor area compared to MPNA nanogels, indicating that Lf-MPNA nanogels selectively accumulated in the tumor tissues with the help of Lf and could be used for the pre-operative MRI diagnosis of the glioma.

To sum up, Lf can be exploited as a targeting ligand conjugated to some nano-enabled carriers to yield an efficient glioma-targeting vector.

2.1.3. LDLR-Mediated Targeting Systems

Low density lipoprotein receptor (LDLR), which is able to prompt the internalization of lipoprotein, has been reported to be highly expressed on the BBB and glioma cells [29,65]. Moreover, some studies on the distribution of LDLR suggested that normal brain tissues, particularly neurons, have relatively low LDLR numbers [66]. All results indicated that the LDLR is a potential molecular target for the selective delivery of anti-tumor agents to glioma [67]. Interestingly, as a natural ligand of the LDLR, LDL once was an ideal carrier for loading and delivering cancer therapeutic and diagnostic agents to targeting sites due to its structure characteristics and chemical properties. First, the size of LDL particles is precisely controlled by its apolipoprotein B-100 (ApoB-100) component through a complex network of amphipathic α-helix protein-lipid interactions [68]. Second, the native LDL is made up of 4563 amino acid residues, which serves as the binding domain for the LDLR and also keeps them soluble in aqueous environments [69]. Most of all, LDL has a highly hydrophobic core that is surrounded by a hydrophilic shell which can make LDL possess multimodal loading capabilities for embedding drugs with different affinities into the shell or the core [70]. However, many studies argued that native LDL is not suitable to act as an appropriate targeting agent because it is difficult to be isolated in large scale and is variable in composition and size. Moreover, large batches of reconstituted LDL cannot be accomplished due to the hard purification of ApoB. Thus, increasing synthetic LDL analogues are developed as replacements of native LDL. Hayavi et al. created a synthetic LDL particle using a lipid emulsion and a peptide composed of LDLR binding domain of ApoB [19]. This LDL particle can deliver cholesterol to cells via the LDLR. In addition, Nikanjam and coworkers developed a synthetic nano-LDL (nLDL) particle containing a lipid emulsion and a unique bifunctional peptide, which could be internalized by glioma cell lines (including SF-767 cells) [28]. After loaded with a lipophilic prodrug, paclitaxel oleate (PO), the glioma-internalizing ability was maintained and glioma cell killing effects were apparently enhanced compared to free drug. What’s more, the cell killing effect could be significantly inhibited by suramin, a LDLR inhibitor. These results suggested the LDLR-mediated mechanism of nLDL.

Some targeting moieties such as ApoB, apolipoprotein E (ApoE), or some peptides corresponding to the LDLR-binding domain of ApoE or ApoB have been proven to be effective in LDLR-targeted therapy of neoplastic diseases [71,72]. However, they are not promising candidates as targeting moieties due to some inherent drawbacks such as protein instability, competition with endogenous
LDL and so on. The group of Jiang proposed that peptide-22, a peptide which showed high affinity for LDLR without competition with endogenous LDL, could be used to transport PTX-loaded NPs across the BBB and subsequently target to brain tumors [29]. The peptide-22-decorated NPs proved its targeting capacity on monolayer BBB model, glioma cells, and a BCECs/C6 glioma co-culture model in vitro. In the meantime, the NPs exhibited stronger brain permeation, glioma targeting, and enhanced chemotherapeutic effect compared to other groups in vivo. These results revealed the feasibility of peptide-22 as a cascade-targeting moiety for LDLR.

2.1.4. LRP-Mediated Targeting Systems

Low density lipoprotein receptor-related protein (LRP) is a type of transmembrane proteins belonging to the LDL receptor family [73,74]. The ubiquitous LRP has been detected up-regulated in numerous human diseases, including glioma [75–77]. It has been reported that LRP is not only overexpressed on glioma cancerous cells but also on the BBB [31]. Moreover, LRP can serve as a common receptor of multiple ligands across the BBB such as melanotransferrin (MTf), Lf, and receptor-associated protein [32,78]. These findings confirmed the role of LRP as an ideal target that can be used for direct delivery of anti-tumor agents to tumor cells. Angiopep-2 peptide, the most famous ligand of LRP, was derived from the common peptidic sequence of the LRP protein ligands, and has shown transcytosis capacity in an in vitro BBB model and the ability to cross the BBB in vivo via the LRP-mediated pathway [79,80]. In recent years, more and more nano vehicles have been fabricated with angiopep-2 to target therapeutic agents to cross the BBB and accumulate in glioma. Ruan and colleagues developed angiopep-2-conjugated DOX-loaded gold NPs to target both BBB and glioma cells [30]. The enhanced cellular uptake and anti-glioma activity of the gold NPs are achieved because angiopep-2 could mediate glioma targeting by specific interaction with LRP. At even earlier time, Fang’s group used angiopep-2 to modify PTX-loading poly(ethylene glycol)-co-poly(ε-caprolactone) (PEG-PCL) NPs [31]. The conjugation of angiopep-2 mediated higher inhibitory effect to U87 MG glioma spheroid and larger amount of NPs in the solid glioma, demonstrating the transportation ability of angiopep-2 across the BBB and enrichment of NPs in glioma selectively. The most exciting thing is that a paclitaxel-angiopep-2 conjugate, GRN1005, has shown safe and fairly tolerant in Phase I clinical trials [81]. Although the preliminary efficacy of GRN1005 in patients with recurrent glioma is modest, the success of brain penetration increased the probability for further clinical trials. MTf, also known as a human melanoma-associated antigen p97, is a homologue of Tf [82]. It is identified as another potential targeting moiety to LRP due to its high affinity. In addition, the specific structure and functions of MTf suggest that it might be an ideal vehicle to transport drug conjugates into the brain [83]. Gabathuler et al. reported that the MTf-adriamycin conjugate significantly increased the survival of mice implanted with C6 glioma cells compared to injections of free adriamycin [32]. In addition, the brain’s uptake of conjugate was over eight-fold higher than that of bovine serum albumin (BSA) or Lf. Taken together, p97 may have the potential to deliver therapeutic drugs to the glioma as a viable effective carrier.

2.1.5. FR-Mediated Targeting Systems

Folate is a low-molecular-weight pterin-based vitamin. FR is essential to capture exogenous folate and various derivatives into the cell cytosol due to the lack of key enzymes of the folate biosynthetic pathway in animal cells [33]. Studies demonstrated that FR is significantly overexpressed on both the BBB and glioma cells, but is sub-expressed in normal brain tissues [34]. These intriguing studies inspired researchers to develop folate-configured nano-enabled carriers as solid tumor targeting vehicles. Cheng and colleagues studied the combined DOX and BCL-2 siRNA therapy using the FR-targeted multifunctional nanoparticle for penetrating the BBB and targeting glioma [84]. The results indicated that FA-conjugated multifunctional nanocarrier could effectively deliver DOX and siRNA into C6 cells in vitro. In vivo experiments showed significant anti-glioma effect and improvement in the survival time of tumor-bearing mice when compared with other formulations, like non-targeting
nanocarriers. Moreover, Chen et al. fabricated FA-conjugated N-(trimethoxysilylpropyl) ethylene diamine triacetic acid (TETT) modified MnO NPs (MnO-TETT-FA) as tumor-specific MRI contrast agents for glioma detection [34]. MR images showed the accumulation of MnO-TETT-FA NPs was more than that of MnO-TETT NPs in the brain of glioma-bearing mice. This additionally illustrated the role of FA in effective drug delivery to the glioma. Additionally, increasing studies give high priority to FR-targeting systems as possible therapeutics for glioma [85,86].

2.1.6. Other Receptor-Mediated Targeting Systems

Beyond the receptors listed above, there are still several receptors being referred as targeting sites for therapeutic agents highly expressed on the BCECs and glioma. One example is the insulin receptor, a membrane glycoprotein present in BCECs as well as glioma cells [35]. Zhang et al. reported that PEGylated immunoliposomes (PILs) modified with 83–14 murine monoclonal antibody, an antibody to the human insulin receptor, could target the gene formulation to brain tumors in vivo [87]. Many studies suggested that humanized 83–14 murine monoclonal antibody had the potential to be used in clinical treatments. Another potential targeting site is the membrane-bound precursor of heparin-binding epidermal growth factor (HB-EGF), which is expressed on both BBB and neuroglial cells and also known as the diphtheria toxin receptor (DTR) [88]. Gaillard et al. utilized a non-toxic mutant of diphtheria toxin (known as CRM197) as the receptor-specific carrier protein which conjugated directly to horseradish peroxidase [89]. Results demonstrated that the DTR seemed to be a human applicable, safe, and effective uptake receptor which could mediate drugs targeting to the brain.

2.2. Glioma-Targeting Systems

Usually, with the aggravation of glioma, the proliferation and invasion of cancer cells will cause a local disruption of the BBB and produce various mediators which can increase the permeability of the capillary endothelium [14,90]. On this occasion, BBB is no longer the main barrier for the drug delivery and some specific receptors on glioma and/or neovasculatures will play crucial roles.

2.2.1. ILR-Mediated Targeting Systems

It has been reported that some interleukin receptors (ILRs) are highly expressed in many tumorous cells because they can contribute to malignant progression and apoptosis resistance of various cancer types, including glioma [91]. Among these ILRs, interleukin-13 receptor (IL-13R) has already been used as a targeting site for mediating nano-enabled delivery systems to glioma.

As one of the inflammatory cytokines, interleukin 13 (IL-13) can bind to two receptor chains, IL-13Ra1 and IL-13Ra2 [92,93]. IL-13Ra2 is reported to be overexpressed on human tumors including glioma cell lines and with a high affinity for IL-13, which makes IL-13Ra2 an attractive target [92,94]. In recent years, a few attempts have been reported to utilize IL-13 to enhance therapeutic effect of glioma [36]. However, as a targeting ligand, several disadvantages, like large molecular weight and easy denaturation, still remain the major challenges of IL-13 [37]. As replacements, some peptides have been developed as targeting ligands for IL-13Ra2. IL-13 peptide (IP), which is consistent with the residues within IL-13 protein, has been demonstrated to possess high affinity for IL-13Ra2. Huang’s group developed IP-modified mesoporous silica NPs (MSN-PEG-IP) as a novel vehicle for delivering DOX to glioma cell lines for the first time [37]. The cellular uptake of MSN-PEG-IP/DOX in U251 glioma cells was significantly higher than that of unmodified NPs, indicating that IP is a potential ligand for fabricating glioma-targeting drug delivery systems. In order to further verify the targeting ability of IP, Huang and colleagues synthesized IP-modified mesoporous silica-coated graphene nanosheets (GSP1) to load DOX for combined therapy of glioma (Figure 2) [54,95]. The novel multifunctional drug delivery system showed higher cellular uptake and cytotoxicity against glioma cells than those of unmodified counterparts. All these results cemented the fact that IP is promising to target nano-enabled theranostic systems to glioma. In addition to IP, other peptides such as IL-13p and Pep-1, have also shown great targeting ability to glioma [91,96].
2.2.2. Integrin-Mediated Targeting Systems

As known, integrin is a member of cell adhesion receptors’ family, playing an important role in tumor growth, invasion, and metastasis [97]. It is composed of α and β subunits. In mammals, 18 α subunits and eight β subunits assemble into 24 integrin receptors [98]. Several integrins have been reported to be highly expressed on the surface of glioma cells and the tumor neovasculatures, but minimally expressed on epithelial and mature endothelial cells [89]. These integrins support some docking sites for drug delivery systems to target to the glioma. Among these receptors, αvβ3, αvβ5, and α5β1 can specifically recognize an RGD motif, which is an exogenous peptide ligand composed of an Arg-Gly-Asp amino acid sequence [99]. In the past several years, RGD and its analogs have been widely investigated for glioma targeting as integrin ligands. Slegrova and coworkers prepared cyclic RGD-modified fluorescent nanodiamonds for targeted drug delivery to glioblastoma cells [38]. Results showed that the fluorescent nanodiamonds possessed high internalization efficacy into U87 cells with conjugation of a cyclic RGD peptide. Furthermore, Peiris et al. used a cyclic RGD peptide to conjugate the chain-like NPs (nanochain) [100]. After being loaded with DOX, the nanochain exhibited a 2.6-fold higher deposition in brain tumors than non-targeted counterpart, illustrating the targeting ability of the cyclic RGD peptide to glioma and the therapeutic efficacy of the nanochain treatment. Therefore, RGD has been identified as a potential targeting ligand for glioma.

3. Dual Ligand-Modified Targeting Systems

Two ligands in this kind of systems may play independent functions to different targeting sites, which then mediate drug delivery systems to overcome different barriers for final glioma targeting.

3.1. Cascade-Targeting Systems

The first strategy of the cascade-targeting systems is to modify the nanocarriers with two kinds of ligands. One of the ligand targets across the BBB, and the other ligand targets tumor cells. Gao et al. came up with a cascade-targeting strategy in order to achieve high and precise brain glioma targeting. They employed PEG-PCL NPs modified with two kinds of targeting ligands [101]. The cellular uptake results suggested that the first stage targeting ligand only targeted to endothelial cells which are the major cellular structure of the BBB, and the second stage ligand only delivered NPs to neuroglial cells that are involved in the majority of CNS diseases including glioma. Another study of them
further indicated that this strategy could increase tumor accumulation and decrease the normal brain distribution [102].

Additionally, the second strategy of the cascade-targeting systems is to build nanocarriers modified with two kinds of ligands, with one targeting to the BBB and tumor cells, and the other promoting the targeting effect. The former ligands are usually some targeting moieties binding to their corresponding receptors, and the latter ligands may be some cell penetrating peptides or some targeting moieties binding to the corresponding receptors, transporters, and so on. Drug delivery system, G4-DOX-PEG-Tf-TAM, was synthesized with Tf and Tamoxifen (TAM) conjugated to polyamidoamine (PAMAM) dendrimer by Li et al. [103]. In this system, Tf was conjugated to mediate the dual-targeting carrier to transport across the BBB and enhance its internalization in glioma. Another targeting moiety, TAM, is an estrogen receptor modulator which was used to improve the BBB permeability. The uptake ability of C6 glioma cells followed the order of G4-DOX-PEG-Tf-TAM > G4-DOX-PEG-Tf > G4-DOX-PEG, indicating that the dual ligand-modified carrier mediated the highest cellular uptake than single ligand-modified or non-targeting carriers. Further study verified the strongest transport efficiency of G4-DOX-PEG-Tf-TAM (6.06%) across the in vitro BBB model compared to that of G4-DOX-PEG-Tf (4.93%) and G4-DOX-PEG (4.62%). He and coworkers developed another dual ligand-mediated cascade-targeting DOX-loaded NPs conjugated with Tf and wheat germ agglutinin (WGA), which has the potential to transfer drugs across the BBB and further target glioma cells [104]. The PAMAM-PEG-WGA-Tf-DOX showed great inhibitory effect to C6 cells after crossing the BBB, compared to PAMAM-PEG-Tf-DOX, PAMAM-PEG-WGA-DOX, and free DOX, indicating better effect by treatments with dual ligand-modified systems. Based on their work, Chen and coworkers prepared polymersomes conjugated with des-octanoyl ghrelin and folate as novel BBB-penetrating and cancer-targeting delivery system [20]. As a 28 residue peptide hormone, des-octanoyl ghrelin was identified as an endogenous ligand of the growth hormone secretagogue receptor, which was observed to transport only in the blood-to-brain direction. Uptake of drugs by the C6 glioma cells through the in vitro BBB model and glioma in in vivo experiments showed that this bifunctional polymersome could enhance BBB transport and tumor accumulation. In addition, a mass of dual cascade-targeting drug delivery systems including daunorubicin-loaded liposome conjugated with p-aminophenyl-α-D-manno-pyranoside (MAN) and Tf, liposome co-modified with T7 and TAT, have been proved to possess stronger BBB-crossing and glioma-accumulating capability compared with single ligand-modified systems [98,105]. Some representative dual targeting systems are summarized in Table 2.

Table 2. Representative dual ligand-modified targeting systems.

| Nanocarrier       | Targeting Moiety | Targeting Site     | Payload            | Reference |
|-------------------|------------------|--------------------|--------------------|-----------|
| PAMAM dendrimer   | Tf               | WGA receptor       | DOX                | [104]     |
| PAMAM dendrimer   | Tf               | ABC transporters   | DOX                | [103]     |
| PEG-PLA NPs       | Lf               | Neuropilin-1       | PTX                | [106]     |
| Liposomes         | Angiopep-2       | LRP                | VEGF siRNA, Docetaxel | [107] |
| Liposomes         | Tf               | —                  | DOX                | [108]     |
| PEG-PCL NPs       | Angiopep-2       | LRP                | DOX                | [102]     |
3.2. Glioma-Targeting Systems

Similar to single ligand-modified glioma-targeting systems, the dual ligand-conjugated systems can specifically target the receptors on the glioma and/or neovasculatures. Gao et al. utilized RGD and IP as ligands to modify polymeric NPs (IRNPs) [111]. The modification of IP and RGD could increase the uptake amount within C6 cells through corresponding receptors and the in vivo study revealed that the fluorescent intensity of DiR-loaded IRNPs in glioma was 3.82-fold that of unmodified NPs. These results demonstrated that the co-modification of RGD and IP could increase the glioma targeting effect, which proved the superiority of dual ligand-modified targeting delivery systems. Although lots of dual ligand-modified targeting systems showed more satisfactory targeting effects, the systems with a single ligand are also other choices which could simplify the preparation of therapeutics. Thus, different research may choose the best way in accordance with requirements in the further.

4. Conclusions

For glioma diagnosis and therapy, a growing number of strategies have been and are being proposed. Compared with other strategies, receptor-mediated drug delivery is most extensively studied lying on several advantages. These systems possess a vital component: nanocarriers modified with targeting moieties. Until now, lots of targeting moieties which are ligands of the receptors on the BBB or glioma have been exploited for BBB-crossing and/or glioma-targeting drug delivery, such as potential peptide ligands. In addition, more and more research has proven that BBB/glioma-specific targeting nanocarrier can help drugs selectively target to the glioma, thus providing higher therapeutic efficiency while simultaneously decreasing systemic toxicity. It seems that the strategy has developed quite well, but so far all the systems except GRN1005 were just used for preclinical studies and none of them have completed Phase II clinical trials. This reminds us that the strategy is still a long way off. It is particularly gratifying that increasing receptors are being found on the BBB or glioma cells, which provide possible targeting sites for developing new receptor-mediated targeting systems. Therefore, extensive research is still required to identify new receptors and corresponding ligands. Most importantly, great efforts should be made to explore and facilitate potential delivery systems for glioma theranosis in future clinical applications.

Acknowledgments: This work was supported by the grants from National Natural Science Foundation of China (81573002), National Key Basic Research Program (2013CB932502) of China (973 Program) and Sino-German Research Project (GZ995).

Author Contributions: The authors all made substantial contributions to conception and design, acquisition and processing of data.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Agnihotri, S.; Burrell, K.E.; Wolf, A.; Jalali, S.; Hawkins, C.; Rutka, J.T.; Zadeh, G. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch. Immunol. Ther. Exp. 2013, 61, 25–41. [CrossRef] [PubMed]
2. Alifieris, C.; Trafalis, D.T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 2015, 152, 63–82. [CrossRef] [PubMed]
3. Paw, I.; Carpenter, R.C.; Watabe, K.; Debinski, W.; Lo, H.W. Mechanisms regulating glioma invasion. *Cancer Lett.* 2015, 362, 1–7. [CrossRef] [PubMed]

4. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; *et al.* Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 2005, 352, 987–996. [CrossRef] [PubMed]

5. Li, X.T.; Ju, R.J.; Li, X.Y.; Zeng, F.; Shi, J.F.; Liu, L.; Zhang, C.X.; Sun, M.G.; Lou, J.N.; Lu, W.L. Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. *Oncoarget* 2014, 5, 6497–6511. [PubMed]

6. Cornago, M.; Garcia-Alberich, C.; Blasco-Angulo, N.; Vall-Llaura, N.; Nager, M.; Herreros, J.; Comella, J.X.; Sanchis, D.; Llovera, M. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. *Cell Death Dis.* 2014, 5. [CrossRef] [PubMed]

7. Parrish, K.E.; Sarkaria, J.N.; Elmquist, W.F. Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier. *Clin. Pharmacol. Ther.* 2015, 97, 336–346. [CrossRef] [PubMed]

8. Van Tellingen, O.; Yetkin-Arik, B.; de Gooijer, M.C.; Wesseling, P.; Wurdinger, T.; de Vries, H.E. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. *Drug Res. Updat.* 2015, 19, 1–12. [CrossRef] [PubMed]

9. Su, Z.; Xing, L.; Xu, Y.; Yang, F.; Zhang, C.; Ping, Q.; Xiao, Y. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain glioma. *Biomaterials* 2013, 34, 6497–6511. [PubMed]

10. Aryal, M.; Vykhodtseva, N.; Zhang, Y.Z.; McDannold, N. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: A safety study. *J. Control. Release* 2015, 204, 60–69. [CrossRef] [PubMed]

11. Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. *Neurosurg. Focus.* 2015, 38. [CrossRef] [PubMed]

12. Ayal, M.; Vykhodtseva, N.; Zhang, Y.Z.; McDannold, N. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: A safety study. *J. Control. Release* 2015, 204, 60–69. [CrossRef] [PubMed]

13. Arora, A.G.; Gaillard, P.J. Drug targeting to the brain. *Annu. Rev. Pharmacol. Toxicol.* 2007, 47, 323–355. [CrossRef] [PubMed]

14. Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 2005, 352, 987–996. [CrossRef] [PubMed]

15. Cui, Y.; Xu, Q.; Chow, P.K.; Wang, D.; Wang, C.H. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. *Biomaterials* 2013, 34, 8511–8520. [CrossRef] [PubMed]

16. Sanchis, D.; Llovera, M. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. *Cell Death Dis.* 2014, 5. [CrossRef] [PubMed]

17. Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 2005, 352, 987–996. [CrossRef] [PubMed]

18. Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 2005, 352, 987–996. [CrossRef] [PubMed]

19. Hayavi, S.; Halbert, G.W. Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture. *Biotechnol. Prog.* 2005, 21, 1262–1268. [CrossRef] [PubMed]

20. Chen, Y.C.; Chiang, C.F.; Chen, L.F.; Liang, P.C.; Hsieh, W.Y.; Lin, W.L. Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. *Biomaterials* 2014, 35, 4066–4081. [CrossRef] [PubMed]

21. Liu, G.; Shen, H.; Yao, J.; Zhang, L.; Jiang, Z.; Sun, T.; Lan, Q.; Zhang, Z. Transferrin modified graphene oxide for glioma-targeted drug delivery: In vitro and in vivo evaluations. *ACS Appl. Mater. Interfaces* 2013, 5, 6909–6914. [CrossRef] [PubMed]

22. Yue, J.; Liu, S.; Wang, R.; Hu, X.; Xie, Z.; Huang, Y.; Jing, X. Fluorescence-labeled immunomicelles: Preparation, in vivo biodistribution, and ability to cross the blood-brain barrier. *Macromol. Biosci.* 2012, 12, 1209–1219. [CrossRef] [PubMed]

23. Liu, S.; Guo, Y.; Huang, R.; Li, J.; Huang, S.; Kuang, Y.; Han, L.; Jiang, C. Gene and doxorubicin co-delivery system for targeting therapy of glioma. *Biomaterials* 2012, 33, 4907–4916. [CrossRef] [PubMed]
24. Kuang, Y.; An, S.; Guo, Y.; Huang, S.; Shao, K.; Liu, Y.; Li, J.; Ma, H.; Jiang, C. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. *Int. J. Pharm.* 2013, 454, 11–20. [CrossRef] [PubMed]

25. Kawamoto, M.; Horibe, T.; Kohno, M.; Kawakami, K. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. *BMC Cancer* 2011, 11, 359. [CrossRef] [PubMed]

26. Kawamoto, M.; Kohno, M.; Horibe, T.; Kawakami, K. Immunogenicity and toxicity of transferrin receptor-targeted hybrid anticancer agent. *Cancer Chemother. Pharmacol.* 2013, 71, 799–807. [CrossRef] [PubMed]

27. Xie, H.; Zhu, Y.; Jiang, W.; Zhou, Q.; Yang, H.; Gu, N.; Zhang, Y.; Xu, H.; Xu, H.; Yang, X. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. *Biomaterials* 2011, 32, 495–502. [CrossRef] [PubMed]

28. Nikanjam, M.; Gibbs, A.R.; Hunt, C.A.; Budinger, T.F.; Forte, T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. *J. Control. Release* 2007, 124, 163–171. [CrossRef] [PubMed]

29. Zhang, B.; Sun, X.; Mei, H.; Wang, Y.; Liao, Z.; Chen, J.; Zhang, Q.; Hu, Y.; Pang, Z.; Jiang, X. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. *Biomaterials* 2013, 34, 9171–9182. [CrossRef] [PubMed]

30. Ruan, S.; Yuan, M.; Zhang, L.; Hu, G.; Chen, J.; Cun, X.; Zhang, Q.; Yang, Y.; He, Q.; Gao, H. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. *Biomaterials* 2015, 37, 425–435. [CrossRef] [PubMed]

31. Xin, H.; Sha, X.; Jiang, X.; Zhang, W.; Chen, L.; Fang, X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. *Biomaterials* 2012, 33, 8167–8176. [CrossRef] [PubMed]

32. Gabathulera, R.; Arthura, G.; Kennarda, M.; Chena, Q.; Tsaia, S.; Yanga, J.; Schoorla, W.; Vitalisb, T.Z.; Jefferies, W.A. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier. *Int. Congr. Ser.* 2005, 1277, 171–184. [CrossRef] [PubMed]

33. Leamon, C.P.; Low, P.S. Folate-mediated targeting: From diagnostics to drug and gene delivery. *Drug Discov. Today* 2001, 6, 44–51. [CrossRef] [PubMed]

34. Chen, N.; Shao, C.; Qu, Y.; Li, S.; Gu, W.; Zheng, T.; Ye, L.; Yu, C. Folic acid-conjugated MnO nanoparticles as a T1 contrast agent for magnetic resonance imaging of tiny brain gliomas. *ACS Appl. Mater. Interfaces* 2014, 6, 19850–19857. [CrossRef] [PubMed]

35. Smith, M.W.; Gumbleton, M. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. *J. Drug Target.* 2006, 14, 191–214. [CrossRef] [PubMed]

36. Thaci, B.; Brown, C.E.; Binello, E.; Werbaneth, K.; Sampath, P.; Sengupta, S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. *Neuro-Oncology* 2014, 16, 1304–1312. [CrossRef] [PubMed]

37. Wang, Y.; Shi, W.; Song, W.; Wang, L.; Liu, X.; Jiang, C.; Huang, R. Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles. *J. Mater. Chem.* 2012, 22, 14608–14616. [CrossRef]

38. Sleserova, J.; Hajek, M.; Rehor, I.; Sedlak, F.; Stursa, J.; Hruby, M.; Cigler, P. Designing the nanobiointerface of fluorescent nanodiamonds: Highly selective targeting of glioma cancer cells. *Nanoscale* 2015, 7, 415–420. [CrossRef] [PubMed]

39. Liu, L.; Wei, Y.; Zhai, S.; Chen, Q.; Xing, D. Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy. *Biomaterials* 2015, 62, 35–46. [CrossRef] [PubMed]

40. Ganz, T.; Nemeth, E. Iron homeostasis in host defence and inflammation. *Nat. Rev. Immunol.* 2015, 15, 500–510. [CrossRef] [PubMed]

41. Sakurai, K.; Sohda, T.; Ueda, S.; Tanaka, T.; Hirano, G.; Yokoyama, K.; Morihara, D.; Aanan, A.; Takeyama, Y.; Irie, M.; et al. Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue. *Hepatogastroenterology* 2014, 61, 426–430. [PubMed]

42. Neves, J.V.; Caldas, C.; Wilson, J.M.; Rodrigues, P.N. Molecular mechanisms of hepcidin regulation in sea bass (*Dicentrarchus labrax*). *Fish Shellfish Immunol.* 2011, 31, 1154–1161. [CrossRef] [PubMed]

43. Daniels, T.R.; Bernabeu, E.; Rodriguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.; Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. *Biochim. Biophys. Acta* 2012, 1820, 291–317. [CrossRef] [PubMed]
44. Dixit, S.; Novak, T.; Miller, K.; Zhu, Y.; Kenney, M.E.; Broome, A.M. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. *Nanoscale* 2015, 7, 1782–1790. [CrossRef] [PubMed]

45. Zhang, P.; Hu, L.; Yin, Q.; Zhang, Z.; Feng, L.; Li, Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: Synthesis, preparation and *in vivo* evaluation. *J. Control. Release* 2012, 159, 429–434. [CrossRef] [PubMed]

46. Jeong, G.W.; Park, S.C.; Choi, C.; Nam, J.P.; Kim, T.H.; Choi, S.K.; Park, J.K.; Nah, J.W. Anticancer effect of gene/peptide co-delivery system using transferrin-grafted LMWSC. *Int. J. Pharm.* 2015, 488, 165–173. [CrossRef] [PubMed]

47. Inoue, S.; Patil, R.; Portilla-Arias, J.; Ding, H.; Konda, B.; Espinoza, A.; Mongayt, D.; Markman, J.L.; Elramissy, A.; Phillips, H.W.; et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. *PLoS ONE* 2012, 7. [CrossRef] [PubMed]

48. Yoshikawa, T.; Pardridge, W.M. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. *J. Pharmacol. Exp. Ther.* 1992, 263, 897–903. [PubMed]

49. Paris-Robidas, S.; Emond, V.; Tremblay, C.; Soulet, D.; Calon, F. *In vivo* labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. *Mol. Pharmacol.* 2011, 80, 32–39. [CrossRef] [PubMed]

50. Du, W.; Fan, Y.; He, B.; Zheng, N.; Yuan, L.; Dai, W.; Zhang, H.; Wang, X.; Wang, J.; Zhang, X.; et al. Bionano interactions of MCF-7 breast tumor cells with a transferrin receptor targeted nanoparticle. *Mol. Pharm.* 2015, 12, 1467–1476. [CrossRef] [PubMed]

51. Han, L.; Li, J.; Huang, S.; Huang, R.; Liu, S.; Hu, X.; Yi, P.; Shan, D.; Wang, X.; Lei, H.; et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. *Biomaterials* 2011, 32, 2989–2998. [CrossRef] [PubMed]

52. Du, W.; Fan, Y.; Zheng, N.; He, B.; Yuan, L.; Zhang, H.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. *Biomaterials* 2013, 34, 794–806. [CrossRef] [PubMed]

53. Zong, T.; Mei, L.; Gao, H.; Shi, K.; Chen, J.; Wang, Y.; Zhang, Q.; Yang, Y.; He, Q. Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT. *J. Pharm. Sci.* 2014, 103, 3891–3901. [CrossRef] [PubMed]

54. Wang, Y.; Lin, T.; Zhang, W.; Jiang, Y.; Jin, H.; He, H.; Yang, V.C.; Chen, Y.; Huang, Y. A Prodrug-Type, MMP-2-Targeting Nanoprobe for Tumor Detection and Imaging. *Theranostics* 2015, 5, 787–795. [CrossRef] [PubMed]

55. Yu, Y.; Jiang, X.; Gong, S.; Feng, L.; Zhong, Y.; Pang, Z. The proton permeability of self-assembled polymersomes and their neuroprotection by enhancing a neuroprotective peptide across the blood-brain barrier after modification with lactoferrin. *Nanoscale* 2014, 6, 3250–3258. [CrossRef] [PubMed]

56. Almond, R.J.; Flanagan, B.F.; Antonopoulos, A.; Haslam, S.M.; Dell, A.; Kimber, I.; Dearman, R.J. Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: Role of glycosylation. *Eur. J. Immunol.* 2013, 43, 170–181. [CrossRef] [PubMed]

57. Raei, M.; Rajabzadeh, G.; Zibaei, S.; Jafari, S.M.; Sani, A.M. Nano-encapsulation of isolated lactoferrin from camel milk by calcium alginate and evaluation of its release. *Int. J. Biol. Macromol.* 2015, 79, 669–673. [CrossRef] [PubMed]

58. Pandey, V.; Gajbhiye, K.R.; Soni, V. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. *Drug Deliv.* 2015, 22, 199–205. [CrossRef] [PubMed]

59. Suzuki, Y.A.; Lonnerdal, B. Baculovirus expression of mouse lactoferrin receptor and tissue distribution in the mouse. *BioMetals* 2004, 17, 301–309. [CrossRef] [PubMed]

60. Talukder, M.J.; Takeuchi, T.; Harada, E. Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. *J. Vet. Med. Sci.* 2003, 65, 957–964. [CrossRef] [PubMed]

61. Huang, R.Q.; Ke, W.L.; Qu, Y.H.; Zhu, J.H.; Pei, Y.Y.; Jiang, C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. *J. Biomed. Sci.* 2007, 14, 121–128. [CrossRef] [PubMed]

62. Fang, J.H.; Lai, Y.H.; Chiu, T.L.; Chen, Y.Y.; Hu, S.H.; Chen, S.Y. Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas. *Adv. Healthc. Mater.* 2014, 3, 1250–1260. [CrossRef] [PubMed]
63. Huang, R.; Ke, W.; Liu, Y.; Jiang, C.; Pei, Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. *Biomaterials* 2008, 29, 238–246. [CrossRef] [PubMed]

64. Fillebeen, C.; Descamps, L.; Dehouck, M.P.; Fanet, L.; Benaissa, M.; Spik, G.; Cecchelli, R.; Pierce, A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. *J. Biol. Chem.* 1999, 274, 7011–7017. [CrossRef] [PubMed]

65. Bertato, M.P.; Oliveira, C.P.; Wächtenberg, B.L.; Lerario, A.C.; Maranhão, R.C. Plasma kinetics of an LDL-like nanoemulsion and lipid transfer to HDL in subjects with glucose intolerance. *Clinics* 2012, 67, 347–353. [CrossRef]

66. Huang, C.L.; Hsiao, I.L.; Lin, H.C.; Wang, C.F.; Huang, Y.J.; Chuang, C.Y. Silver nanoparticles affect on gene expression of inflammatory and neurodegenerative responses in mouse brain neural cells. *Environ. Res.* 2015, 136, 253–263. [CrossRef] [PubMed]

67. Jain, A.J.K. Low density lipoproteins mediated nanoplatforms for cancer targeting. *J. Nanopart. Res.* 2013, 15. [CrossRef]

68. Kader, A.; Pater, A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. *J. Control. Release* 2002, 80, 29–44. [CrossRef]

69. Chakraborty, S.; Cai, Y.; Tarr, M.A. [PubMed]

70. Chu, A.C.; Tsang, S.Y.; Lo, E.H.; Fung, K.P. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. *Life Sci.* 2001, 70, 591–601. [CrossRef]

71. Sarkar, G.; Curran, G.L.; Mahlum, E.; Decklever, T.; Benaissa, M.; Spik, G.; Cecchelli, R.; Pierce, A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. *J. Biol. Chem.* 1999, 274, 7011–7017. [CrossRef] [PubMed]

72. Spencer, B.J.; Verma, I.M. Targeted delivery of proteins across the blood-brain barrier. *J. Cell Sci.* 2004, 117, 106–118. [CrossRef] [PubMed]

73. Bertrand, Y.; Currie, J.C.; Poirier, J.; Demeule, M.; Abulrob, A.; Fatehi, D.; Stanimirovic, D.; Sartelet, H.; Castaigne, J.P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein 1. *Br. J. Cancer* 2011, 105, 1697–1707. [CrossRef] [PubMed]

74. Bell, R.D.; Sagare, A.P.; Friedman, A.E.; Bedi, G.S.; Holtzman, D.M.; Deane, R.; Zlokovic, B.V. Transport pathways for clearance of human Alzheimer’s amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. *J. Cereb. Blood Flow Metab.* 2007, 27, 909–918. [CrossRef] [PubMed]

75. Pires, L.A.; Hegg, R.; Freitas, F.R.; Tavares, E.R.; Almeida, C.P.; Baracat, E.C.; Maranhão, R.C. Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer. *Braz. J. Med. Biol. Res.* 2012, 45, 557–564. [CrossRef] [PubMed]

76. Donahue, J.E.; Flaherty, S.L.; Johanson, C.E.; Duncan, J.R.; Silverberg, G.D.; Miller, M.C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. *Acta Neuropathol.* 2006, 112, 405–415. [CrossRef] [PubMed]

77. Hendricks, D.A.; Koning, N.; Schuurman, K.G.; van Strien, M.E.; van Eden, C.G.; Hamann, J.; Huitinga, I. Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. *J. Neuropathol. Exp. Neurol.* 2013, 72, 106–118. [CrossRef] [PubMed]

78. Pan, W.; Kastin, A.J.; Zankel, T.C.; van Kerkhof, P.; Terasaki, T.; Bu, G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. *J. Cell Sci.* 2004, 117, 5071–5078. [CrossRef] [PubMed]

79. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J.P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain. *J. Pharmacol. Exp. Ther.* 2008, 324, 1064–1072. [CrossRef] [PubMed]

80. Demeule, M.; Currie, J.C.; Bertrand, Y.; Che, C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J.P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. *J. Neurochem.* 2008, 106, 1534–1544. [CrossRef] [PubMed]

81. Drappatz, J.; Brenner, A.; Wong, E.T.; Eichler, A.; Schiff, D.; Groves, M.D.; Mikkelsen, T.; Rosenfeld, S.; Sarantopoulos, J.; Meyers, C.A.; et al. Phase I study of GRN1005 in recurrent malignant glioma. *Clin. Cancer Res.* 2013, 19, 1567–1576. [CrossRef] [PubMed]
82. Suryo, R.Y.; Bal, S.; Loh, K.H.; Yu, Y.; Richardson, D.R. Melanotransferrin: Search for a function. *Biochim. Biophys. Acta* **2012**, *1820*, 237–243.

83. Karkan, D.; Pfeifer, C.; Vitalis, T.Z.; Arthur, G.; Ujjie, M.; Chen, Q.; Tsai, S.; Koliatis, G.; Gabathuler, R.; Jefferies, W.A. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. *PLoS ONE* **2008**, *3*. [CrossRef]

84. Cheng, D.; Cao, N.; Chen, J.; Yu, X.; Shuai, X. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. *Biomaterials* **2012**, *33*, 1170–1179. [CrossRef] [PubMed]

85. Lee, K.D.; Choi, S.H.; Kim, D.H.; Lee, H.Y.; Choi, K.C. Self-organized nanoparticles based on chitosan-folic acid and dextran succinate-doxorubicin conjugates for drug targeting. *Arch. Pharm. Res.* **2014**, *37*, 1546–1553. [CrossRef] [PubMed]

86. Chen, Y.C.; Chiang, C.F.; Wu, S.K.; Chen, L.F.; Hsieh, W.Y.; Lin, W.L. Targeting microbubbles-carrying TGFβ1 inhibitor combined with ultrasound sonication induce BBB/BTB disruption to enhance nanomedicine treatment for brain tumors. *J. Control. Release* **2015**, *211*, 53–62. [CrossRef] [PubMed]

87. Zhang, Y.; Jeong, L.H.; Boado, R.J.; Pardridge, W.M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. *J. Gene Med.* **2002**, *4*, 183–194. [CrossRef] [PubMed]

88. Kuo, Y.C.; Liu, Y.C. Cardiolipin-incorporated liposomes with surface CRM197 for enhancing neuronal survival against neurotoxicity. *Int. J. Pharm.* **2014**, *473*, 334–344. [CrossRef] [PubMed]

89. Gururangan, S.; Friedman, H.S. Innovations in design and delivery of chemotherapy for brain tumors. *Neuroimaging Clin. N. Am.* **2012**, *2*, 583–597. [CrossRef]

90. Zhan, C.; Lu, W. The blood-brain/tumor barriers: Challenges and chances for malignant gliomas targeted drug delivery. *Curr. Pharm. Biotechnol.* **2012**, *13*, 2380–2387. [CrossRef] [PubMed]

91. Kioi, M.; Seetharam, S.; Puri, R.K. Targeting IL-13RA2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. *Mol. Cancer Ther.* **2008**, *7*, 1579–1587. [CrossRef] [PubMed]

92. Gao, H.; Yang, Z.; Zhang, S.; Cao, S.; Pang, Z.; Yang, X.; Jiang, X. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. *J. Control. Release* **2013**, *172*, 921–928. [CrossRef] [PubMed]

93. Geskin, L.J.; Viragova, S.; Stolz, D.B.; Fuschiotti, P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. *Blood* **2015**, *125*, 2798–2805. [CrossRef] [PubMed]

94. Suzuki, A.; Leland, P.; Kobayashi, H.; Choyke, P.L.; Jagoda, E.M.; Inoue, T.; Joshi, B.H.; Puri, R.K. Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an orthotopic mouse model of human glioma. *J. Nucl. Med.* **2014**, *55*, 1323–1329. [CrossRef] [PubMed]

95. Wang, Y.; Wang, K.; Zhao, J.; Liu, X.; Bu, J.; Yan, X.; Huang, R. Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma. *J. Am. Chem. Soc.* **2013**, *135*, 4799–4804. [CrossRef] [PubMed]

96. Wang, B.; Lv, L.; Wang, Z.; Zhao, Y.; Wu, L.; Fang, X.; Xu, Q.; Xin, H. Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor a2-mediated endocytosis. *Biomaterials* **2014**, *35*, 5897–5907. [CrossRef] [PubMed]

97. Park, E.J.; Yuki, Y.; Kiyono, H.; Shimaoka, M. Structural basis of blocking integrin activation and deactivation for anti-inflammation. *J. Biomed. Sci.* **2015**, *22*. [CrossRef] [PubMed]

98. Hood, J.D.; Cheresh, D.A. Role of integrins in cell invasion and migration. *Nat. Rev. Cancer* **2002**, *2*, 91–100. [CrossRef] [PubMed]

99. Zitzmann, S.; Ehemann, V.; Schwab, M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. *Cancer Res.* **2002**, *62*, 5139–5143. [PubMed]

100. Peiris, P.M.; Abramowski, A.; Mcginnity, J.; Doolittle, E.; Toy, R.; Gopalakrishnan, R.; Shah, S.; Bauer, L.; Ghaghada, K.B.; Hoimes, C.; et al. Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. *Cancer Res.* **2015**, *75*, 1356–1365. [CrossRef] [PubMed]

101. Gao, H.; Qian, J.; Cao, S.; Yang, Z.; Pang, Z.; Pan, S.; Fan, L.; Xi, Z.; Jiang, X.; Zhang, Q. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. *Biomaterials* **2012**, *33*, 5115–5123. [CrossRef] [PubMed]
102. Huile, G.; Shuaiqi, P.; Zhi, Y.; Shijie, C.; Chen, C.; Xinguo, J.; Shun, S.; Zhiqing, P.; Yu, H. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. *Biomaterials* 2011, 32, 8669–8675. [CrossRef] [PubMed]

103. Li, Y.; He, H.; Jia, X.; Lu, W.L.; Lou, J.; Wei, Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. *Biomaterials* 2012, 33, 3899–3908. [CrossRef] [PubMed]

104. He, H.; Li, Y.; Jia, X.R.; Du, J.; Ying, X.; Lu, W.L.; Lou, J.N.; Wei, Y. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. *Biomaterials* 2011, 32, 478–487. [CrossRef] [PubMed]

105. Zong, T.; Mei, L.; Gao, H.; Cai, W.; Zhu, P.; Shi, K.; Chen, J.; Wang, Y.; Gao, F.; He, Q. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. *Mol. Pharm.* 2014, 11, 2346–2357. [CrossRef] [PubMed]

106. Miao, D.; Jiang, M.; Liu, Z.; Gu, G.; Hu, Q.; Kang, T.; Song, Q.; Yao, L.; Li, W.; Gao, X.; et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. *Mol. Pharm.* 2014, 11, 90–101. [CrossRef] [PubMed]

107. Yang, Z.Z.; Li, J.Q.; Wang, Z.Z.; Dong, D.W.; Qi, X.R. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. *Biomaterials* 2014, 35, 5226–5239. [CrossRef] [PubMed]

108. Zheng, C.; Ma, C.; Bai, E.; Yang, K.; Xu, R. Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. *Int. J. Clin. Exp. Med.* 2015, 8, 1658–1668. [PubMed]

109. Agrawal, U.; Chashoo, G.; Sharma, P.R.; Kumar, A.; Saxena, A.K.; Vyas, S.P. Tailored polymer-lipid hybrid nanoparticles for the delivery of drug conjugate: Dual strategy for brain targeting. *Colloids Surf. B* 2015, 126, 414–425. [CrossRef] [PubMed]

110. Yue, P.J.; He, L.; Qiu, S.W.; Li, Y.; Liao, Y.J.; Li, X.P.; Xie, D.; Peng, Y. OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. *Mol. Cancer* 2014, 13. [CrossRef] [PubMed]

111. Gao, H.; Xiong, Y.; Zhang, S.; Yang, Z.; Cao, S.; Jiang, X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovascularature dual targeting delivery and elevated tumor penetration. *Mol. Pharm.* 2014, 11, 1042–1052. [CrossRef] [PubMed]

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).